Successful Antiviral and Antituberculosis Treatment With Pegylated Interferon-alfa and Ribavirin in a Chronic Hepatitis C Patient With Pulmonary Tuberculosis

被引：17
|
作者：
Tsai, Ming-Chao [1 ]
Lin, Meng-Chih [2 ]
Hung, Chao-Hung [1 ]
机构：
[1] Chang Gung Univ, Kaohsiung Med Ctr, Chang Gung Mem Hosp, Coll Med,Div Hepatogastroenterol,Dept Internal Me, Kaohsiung, Taiwan
[2] Chang Gung Univ, Kaohsiung Med Ctr, Chang Gung Mem Hosp, Coll Med,Div Pulm & Crit Care Med,Dept Internal M, Kaohsiung, Taiwan
来源：
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | 2009年 / 108卷 / 09期
关键词：
chronic hepatitis C; peginterferon alfa-2a; pulmonary tuberculosis; sustained virological response; PLUS RIBAVIRIN; THERAPY; MANAGEMENT; INFECTION; TAIWAN;
D O I：
10.1016/S0929-6646(09)60400-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Pulmonary tuberculosis is a rare side effect of antiviral treatment for chronic hepatitis C. We present the case of 55-year-old woman with chronic hepatitis C, who developed pulmonary tuberculosis after receiving 8 weeks of peginterferon alfa-2a plus ribavirin therapy. Antituberculous treatment was started and antiviral agents were given continually at adjusted doses. Her symptoms of cough with blood-tinged sputum improved I month after antituberculous therapy. Treatment for hepatitis C and pulmonary tuberculosis were completed after 6 months. At 6 months after antiviral therapy, a sustained virological response was achieved and follow-up chest radiography showed a marked regressive change. This is believed to be the first case report of complete remission from hepatitis C and pulmonary tuberculosis treated concurrently with antiviral and antituberculous agents. [J Formos Med Assoc 2009; 108(9):746-750]
引用
收藏
页码：746 / 750
页数：5
相关论文
共 50 条
  • [41] Ribavirin Impairs Salivary Gland Function in Hepatitis C Patients During Combination Treatment With Pegylated Interferon Alfa-2a
    Aghemo, Alessio
    Rumi, Maria Grazia
    Monico, Sara
    Banderali, Matteo
    Russo, Antonio
    Ottaviani, Francesco
    Vigano, Mauro
    D'Arnbrosio, Roberta
    Colombo, Massimo
    HEPATITIS MONTHLY, 2011, 11 (11) : 919 - 925
  • [42] Influence of pegylated interferon and ribavirin on insulin resistance and metabolic factors in chronic hepatitis C
    Altin, Zeynep
    Diniz, Gulden
    Colak, Ayfer
    Koyuncu, Betul
    Ozer, Serhat
    Aslan, Fatih
    Unsal, Belkis
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2019, 44 (02): : 170 - 176
  • [43] Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alfa-2b and ribavirin for chronic hepatitis C
    Nishiofuku, Mariko
    Tsujimoto, Tatsuhiro
    Matsumura, Yoshinobu
    Toyohara, Masahisa
    Yoshiji, Hitoshi
    Yamao, Jun-ichi
    Fukui, Hiroshi
    Yoshikawa, Masahide
    INTERNAL MEDICINE, 2006, 45 (07) : 483 - 484
  • [44] EXPECTORATION OF LARGE BRONCHIAL CASTS SECONDARY TO THE TREATMENT OF CHRONIC HEPATITIS C WITH PEGYLATED INTERFERON AND RIBAVIRIN
    Affonso de Araujo, Evaldo Stanislau
    Campos, Aleia Faustina
    Yamashiro, Juliana
    Mello, Evandro Sobrosa
    Takagaki, Teresa
    Barone, Antonio Alci
    CLINICS, 2010, 65 (07) : 745 - 748
  • [45] Efficacy and Safety of Pegylated Interferon Combined with Ribavirin for the Treatment of Older Patients with Chronic Hepatitis C
    Huang, Chung-Feng
    Yang, Jeng-Fu
    Dai, Chia-Yen
    Huang, Jee-Fu
    Hou, Nai-Jen
    Hsieh, Ming-Yen
    Lin, Zu-Yau
    Chen, Shinn-Cherng
    Hsieh, Ming-Yuh
    Wang, Liang-Yen
    Chang, Wen-Yu
    Chuang, Wan-Long
    Yu, Ming-Lung
    JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (05) : 751 - 759
  • [46] Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin
    Striki, A.
    Manolakopoulos, S.
    Deutsch, M.
    Mela, M.
    Kalafateli, M.
    Schini, M.
    Anagnostou, O.
    Triantos, C.
    Andreadis, I.
    Ketikoglou, I.
    Papatheodoridis, G.
    Pectasides, D.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 (09) : 624 - 632
  • [47] ITPA Gene Variant May Protect against Anemia Induced During Pegylated Interferon Alfa and Ribavirin Combination Treatment in Ukrainian Patients with Chronic Hepatitis C
    Kucherenko, A.
    Pampukha, V.
    Bobrova, I.
    Moroz, L.
    Livshits, L.
    CYTOLOGY AND GENETICS, 2015, 49 (02) : 109 - 112
  • [48] Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6
    Kapol, Nattiya
    Lochid-amnuay, Surasit
    Teerawattananon, Yot
    BMC GASTROENTEROLOGY, 2016, 16
  • [49] Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin
    Lindh, M.
    Arnholm, B.
    Bjorkman, P.
    Hellstrand, K.
    Lagging, M.
    Nilsson, S.
    Wahlberg, T.
    Wallmark, E.
    Weiland, O.
    Wejstal, R.
    Westin, J.
    Widell, A.
    Norkrans, G.
    JOURNAL OF VIRAL HEPATITIS, 2013, 20 (04) : e82 - e89
  • [50] Treatment of Genotype 4 Hepatitis C Recurring After Liver Transplantation Using a Combination of Pegylated Interferon Alfa-2a and Ribavirin
    Al-Hamoudi, Waleed
    Mohamed, Hazem
    Abaalkhail, Faisal
    Kamel, Yaser
    Al-Masri, Nasser
    Allam, Naglaa
    Alqahtani, Saleh
    Al-Sofayan, Mohammed
    Khalaf, Hatem
    Al-Sebayel, Mohammed
    Al-Jedai, Ahmed
    Abdo, Ayman
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (06) : 1848 - 1852
12345